Robust statistical inference for the matched net benefit and the matched win ratio using prioritized composite endpoints
Roland A. Matsouaka, Adrian Coles

TL;DR
This paper proposes a robust statistical inference method for the net benefit and win ratio in composite endpoints, addressing limitations of large-sample assumptions especially in small samples or extreme proportions.
Contribution
It introduces a new test statistic, sample size formula, and MOVER-based confidence intervals for NB and WR, improving accuracy in small or boundary cases.
Findings
MOVER confidence intervals perform well in small samples.
Proposed methods outperform existing ones near boundary proportions.
Simulation studies validate the robustness of the new approach.
Abstract
As alternatives to the time-to-first-event analysis of composite endpoints, the {\it net benefit} (NB) and the {\it win ratio} (WR) -- which assess treatment effects using prioritized component outcomes based on clinical importance -- have been proposed. However, statistical inference of NB and WR relies on a large-sample assumptions, which can lead to an invalid test statistic and inadequate, unsatisfactory confidence intervals, especially when the sample size is small or the proportion of wins is near 0 or 1. In this paper, we develop a systematic approach to address these limitations in a paired-sample design. We first introduce a new test statistic under the null hypothesis of no treatment difference. Then, we present the formula to calculate the sample size. Finally, we develop the confidence interval estimations of these two estimators. To estimate the confidence intervals, we…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAdvanced Causal Inference Techniques · Statistical Methods in Clinical Trials · Health Systems, Economic Evaluations, Quality of Life
